https://www.selleckchem.com/products/dc661.html
Based on its broad efficacy and limited toxicity, OmoMYC is currently being developed for evaluation in clinical trials. Although no compound directly targeting MYC has yet progressed to clinical testing, APTO-253, which partly acts by decreasing expression of MYC, is currently undergoing a phase I clinical trial in patients with relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome.Veterinarians are the main source of information for farmers regarding the responsible use of antibiotics in farm animals and how to reduce t
Like
Comment
Share
